Pharmabiz

Lupin receives US FDA approval for dapagliflozin tablets

Lupin Limited (Lupin), a global pharmaceutical leader, announced that it has received approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application for ...
Pharmabiz

Artivion announces Endospan’s NEXUS Aortic Arch System receives US FDA approval

Artivion announces Endospan’s NEXUS Aortic Arch System receives US FDA approval: Atlanta Wednesday, April 8, 2026, 14:00 Hrs [IST] Artivion, Inc., a leading cardiac and vascular ...
Pharmabiz

Nuvalent submits NDA to US FDA for neladalkib in TKI pre-treated advanced ALK-positive NSCLC

Nuvalent submits NDA to US FDA for neladalkib in TKI pre-treated advanced ALK-positive NSCLC: Cambridge, Massachusetts Wednesday, April 8, 2026, 13:00 Hrs [IST] Nuvalent, Inc., a ...
Pharmabiz

TARTAN-HF trial reveals simple heart-failure screening could help identify undiagnosed heart failure in diabetes

TARTAN-HF trial reveals simple heart-failure screening could help identify undiagnosed heart failure in diabetes: Our Bureau, Mumbai Wednesday, April 8, 2026, 12:15 Hrs [IST] The ...
Pharmabiz

Amgen announces positive phase 3 results for subcutaneous Tepezza in adults living with moderate-to-severe active thyroid eye disease

Amgen announces positive phase 3 results for subcutaneous Tepezza in adults living with moderate-to-severe active thyroid eye disease: Thousand Oaks, California Wednesday, April 8 ...
Pharmabiz

InVera Medical receives US FDA 510(k) clearance for InVera Infusion Device, a novel non-thermal catheter for enhanced infusion of sclerosant for CVD

InVera Medical receives US FDA 510(k) clearance for InVera Infusion Device, a novel non-thermal catheter for enhanced ...
Pharmabiz

Upsher-Smith introduces generic version of Ciprodex sterile Otic suspension

Upsher-Smith introduces generic version of Ciprodex sterile Otic suspension: Maple Grove, Minnesota Upsher-Smith Laboratories, LLC (Upshe ...
Pharmabiz

Sanofi’s lunsekimig meets primary and key secondary endpoints in phase 2 respiratory studies in asthma and CRSwNP

Sanofi’s lunsekimig meets primary and key secondary endpoints in phase 2 respiratory studies in asthma and CRSwNP: Paris Wednesday, April 8, 2026, 09:00 Hrs [IST] Phase 2 studie ...
Opinion
PharmabizOpinion

Biggest opportunity lies in building global scale facilities as cos tap PLI, RDI incentives: Kiran Mazumdar-Shaw

Biggest opportunity lies in building global scale facilities as cos tap PLI, RDI incentives: Kiran Mazumdar-Shaw: Nandita Vijayasimha, Bengaluru Wednesday, April 8, 2026, 08:00 Hr ...
Pharmabiz

Experts assess how patent expiry of semaglutide is reshaping GLP-1 pricing and patient access

Experts assess how patent expiry of semaglutide is reshaping GLP-1 pricing and patient access: Shardul Nautiyal, Mumbai Wednesday, April 8, 2026, 08:00 Hrs [IST] India is experien ...
Pharmabiz

DTAB not to pursue proposal to mandate free medicine from pharma cos as part of CSR

DTAB not to pursue proposal to mandate free medicine from pharma cos as part of CSR: Gireesh Babu, New Delhi Wednesday, April 8, 2026, 08:00 Hrs [IST] The Drugs Technical Advisory ...
Pharmabiz

CBC–RIS partnership signals AI-led transformation for healthcare and pharma: Experts

CBC–RIS partnership signals AI-led transformation for healthcare and pharma: Experts: Shardul Nautiyal, Mumbai Wednesday, April 8, 2026, 08:00 Hrs [IST] In a landmark move to st ...